Bruker Reports Full-Year 2025 Net Loss, Significant Profitability Decline, and $127M in Impairment Charges Amidst Revenue Headwinds

summarizeSummary

Bruker Corporation reported a net loss for full-year 2025, a sharp decline in profitability, and over $127 million in impairment charges, primarily due to macroeconomic conditions, tariffs, and reduced demand in key markets.

check_boxKey Events

• Shift to Net Loss for Common Shareholders

  The company reported a net loss of $22.5 million attributable to common shareholders for the year ended December 31, 2025, a significant reversal from a net income of $113.1 million in 2024.

• Significant Decline in Profitability

  Gross profit margin decreased from 49.0% in 2024 to 45.9% in 2025, and operating income margin fell sharply from 7.5% to 2.0% over the same period.

• Substantial Impairment Charges

  Bruker recorded a $96.5 million goodwill impairment charge related to its Bruker Spatial Biology and Automation reporting units, along with $30.7 million in intangible asset impairment charges in 2025.

• Organic Revenue Decline

  Non-GAAP organic revenue experienced a 3.7% year-on-year decrease, contrasting with a 4.0% growth in the prior year, driven by slower demand in industrial, semiconductor, biopharma, and clinical MRI markets.

auto_awesomeAnalysis

Bruker Corporation's full-year 2025 results, following the preliminary Q4/FY25 results reported in the 8-K on February 12, 2026, reveal a substantial deterioration in financial performance. The company shifted from a net income of $113.1 million in 2024 to a net loss of $22.5 million for common shareholders in 2025. This decline was driven by a significant drop in gross profit margin (from 49.0% to 45.9%) and operating income margin (from 7.5% to 2.0%), alongside a 3.7% organic revenue decline. Material non-cash charges, including a $96.5 million goodwill impairment and $30.7 million in intangible asset impairment, further impacted profitability. The company also incurred $77.4 million in restructuring costs and faced headwinds from U.S. tariffs and foreign exchange rates. While the issuance of $690 million in mandatory convertible preferred stock in September 2025 helped repay existing debt, the overall financial picture reflects significant challenges and a re-evaluation of asset values. The resolution of two major patent litigations with payments totaling $104 million, while removing uncertainty, adds to the cash outflows.